ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GE Healthcare is acquiring Switzerland's Biacore International for about $390 million. Pfizer, which has a 41% shareholding in Biacore, has agreed to the transaction, saying the sale is in keeping with a focus on its core pharmaceutical business. Biacore supplies protein-interaction analysis systems for biomarker and drug discovery. GE Healthcare CEO Joseph M. Hogan says Biacore is complementary with GE's existing protein sciences business.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X